Hikal Limited provides contract research, development, and manufacturing services for pharmaceutical and specialty-chemical companies. Its integrated capabilities cover APIs, intermediates, and complex chemical processes. Increasing outsourcing by global pharmaceutical and chemical companies provides long-term opportunities. Expansion of CDMO capabilities and higher-value products can improve the business mix. Regulatory compliance, customer concentration, project execution, raw-material costs, and global pharma demand remain important considerations.
| Market cap | Sales (TTM) | Net profit (TTM) | P/E | EPS (TTM) | P/B | ROE | ROE previous year | ROCE | Debt / equity | Free cash flow | EV / EBITDA | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹2,683 cr | ₹1,735 cr | ₹-34 cr | — | -2.74 | 2.24 | -4.0% | 7.4% | -0.8% | 0.57 | ₹154 cr | 22.6 | 1.61 |
| Quarter | Sales ₹ cr | Net profit ₹ cr | EPS | EPS YoY | Sales YoY | Net margin |
|---|---|---|---|---|---|---|
| Jun 2026 | 403 | -7 | -0.60 | — | +5.9% | -1.8% |
| Mar 2026 | 519 | 14 | 1.17 | -71.2% | -6.0% | 2.8% |
| Dec 2025 | 494 | -6 | -0.48 | -134.5% | +10.4% | -1.2% |
| Sep 2025 | 318 | -35 | -2.83 | -291.2% | -29.7% | -11.0% |
| Jun 2025 | 380 | -22 | -1.82 | -543.9% | -6.5% | -5.9% |
| Mar 2025 | 552 | 50 | 4.07 | +47.5% | +7.4% | 9.1% |
| Dec 2024 | 448 | 17 | 1.39 | +6.1% | +0.0% | 3.8% |
| Sep 2024 | 453 | 18 | 1.48 | +45.1% | +4.1% | 4.0% |
| Check | Result |
|---|---|
| Latest quarter EPS up 25%+ on a year ago | — Not assessable |
| EPS growth accelerating over 3 quarters | — Not assessable |
| Sales up 25%+, or sales growth accelerating | ✗ Fail |
| Annual EPS up 25%+ in each of the last 2 years | ✗ Fail |
| Net margin above the same quarter last year | ✓ Pass |
| Method | Checks | Score | Verdict |
|---|---|---|---|
| Minervini | ✓ Close above the 150- and 200-day averages ✓ 150-day above 200-day ✗ 200-day rising for a month ✓ 50-day above the 150- and 200-day ✗ Close above the 50-day ✓ At least 25% above the 52-week low · low 147.08 ✓ Within 25% of the 52-week high · high 256.15 ✗ RS percentile 70 or more · RS 43 Trend template - the gate, measured: a modest 21-day edge. | 5/8 | 5 of 8 |
| Weinstein | Stan Weinstein's stage analysis on the 30-week moving average. | Stage 2 - advancing | |
| CAN SLIM | — C latest quarter EPS up 25%+ ✗ A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held ✗ N within 15% of the 52-week high · high 256.15 ✓ S more volume on up days than down days (50 sessions) · 4.08x ✗ L RS percentile 80 or more · RS 43 — I institutional sponsorship rising · shareholding not collected yet ✓ M market in an uptrend (40%+ of stocks above their 200-day) · breadth 45% William O'Neil's growth-leader checklist. | 2/5 | Weak |
| Darvas | ✗ New 52-week high in the last 120 sessions Darvas needs a new 52-week high to start a box. | 10/100 | No box |
| Turtle | ✗ Close above the prior 55-session high · 257.00 ✗ Close above the prior 20-session high · 240.88 ✗ Close below the prior 20-session low · 207.21 Donchian channel breakout - the Turtle traders' entry. | No signal | |
| Greenblatt | — Earnings yield (EBITDA / EV) · 4.4% — Return on capital (ROCE) · -0.8% Joel Greenblatt's Magic Formula: good businesses at good prices, ranked across all companies. Earnings yield uses EBITDA, as EBIT is not held separately. | 8/100 | Weak |
| Graham | Needs positive earnings and book value. | Not assessable | |
| Piotroski | ✗ Profitable (ROA > 0) ✓ Operating cash flow positive ✗ ROA rising ✓ Cash flow above net profit (earnings quality) ✗ Long-term debt / assets falling ✓ Current ratio rising · 1.30 ✓ No new shares issued ✗ Margin rising (net margin) ✗ Asset turnover rising Joseph Piotroski's F-score, FY 2025 -> 2026. | 4/9 | Weak |
| Stock | 1M % | 3M % | 6M % | 1Y % | 3Y % | 5Y % | P/E | P/B | ROE % | ROCE % | ROA % | D/E | EV/EBITDA | ₹ Cr | Sales TTM ₹ Cr | Profit TTM ₹ Cr | EPS | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HIKAL this stock | -3.9 | -4.4 | +15.3 | -9.5 | -24.3 | -58.1 | — | 2.24 | -4.0 | -0.8 | — | 0.57 | 22.6 | 2,683 | 1,735 | -34 | -2.7 | 1.61 |
| BODALCHEM | -14.3 | +149.1 | +142.6 | +175.9 | +104.7 | +20.3 | 30.1 | 1.78 | 4.2 | 6.7 | — | 0.69 | 14.2 | 2,065 | 2,267 | 69 | 5.5 | 0.70 |
| RPEL | +7.6 | +38.6 | +149.7 | +161.5 | — | — | 115.8 | 28.99 | 25.0 | 31.2 | — | 0.02 | 85.7 | 8,164 | 315 | 70 | 15.3 | 1.42 |
| FCL | -2.1 | +41.7 | +142.9 | +128.2 | +70.0 | +356.5 | 43.9 | 7.36 | 13.5 | 18.3 | — | 0.01 | 39.5 | 6,499 | 1,012 | 148 | 1.3 | 1.46 |
| AETHER | -6.7 | +4.9 | +28.3 | +104.1 | +70.3 | — | 85.6 | 8.22 | 9.4 | 11.6 | — | 0.18 | 55.5 | 20,191 | 1,224 | 235 | 17.8 | 0.75 |
| KRISHANA | +18.3 | +46.5 | +66.7 | +87.6 | +322.8 | +1076.5 | 33.5 | 11.74 | 38.1 | 27.3 | — | 1.31 | 22.8 | 6,581 | 2,555 | 197 | 6.4 | 1.04 |
| OAL | +21.4 | +78.0 | +98.3 | +85.2 | +69.9 | -28.9 | 395.2 | 3.16 | 0.5 | 4.5 | — | 0.61 | 32.3 | 2,101 | 1,065 | 5 | 1.6 | 0.97 |
| NEOGEN | -0.3 | +13.7 | +66.1 | +70.0 | +43.2 | +81.2 | 186.7 | 8.32 | 3.6 | 6.6 | — | 1.63 | 56.6 | 6,795 | 926 | 36 | 13.3 | 0.84 |
| NAVINFLUOR | -5.1 | +3.7 | +26.0 | +59.6 | +123.5 | +111.1 | 52.9 | 10.52 | 20.1 | 21.4 | — | 0.31 | 37.8 | 41,822 | 3,634 | 790 | 154.2 | 0.78 |
| VALIANTORG | +9.1 | +74.3 | +72.0 | +59.4 | -0.5 | -70.1 | 24.0 | 1.72 | 4.5 | 6.2 | — | 0.33 | 15.5 | 1,305 | 766 | 54 | 19.4 | 1.02 |
| ICIL | -5.3 | +8.0 | +58.0 | +58.8 | +74.0 | +46.7 | 55.6 | 3.56 | 5.5 | 8.7 | — | 0.46 | 21.0 | 8,394 | 4,390 | 151 | 7.6 | 1.50 |